These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
720 related articles for article (PubMed ID: 20223018)
41. Recurrent Mutations in Łukomska A; Menkiszak J; Gronwald J; Tomiczek-Szwiec J; Szwiec M; Jasiówka M; Blecharz P; Kluz T; Stawicka-Niełacna M; Mądry R; Białkowska K; Prajzendanc K; Kluźniak W; Cybulski C; Dębniak T; Huzarski T; Tołoczko-Grabarek A; Byrski T; Baszuk P; Narod SA; Lubiński J; Jakubowska A Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670479 [TBL] [Abstract][Full Text] [Related]
42. Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers. Menkiszak J; Chudecka-Głaz A; Gronwald J; Cymbaluk-Płoska A; Celewicz A; Świniarska M; Wężowska M; Bedner R; Zielińska D; Tarnowska P; Jakubowicz J; Kojs Z J Ovarian Res; 2016 Feb; 9():11. PubMed ID: 26928677 [TBL] [Abstract][Full Text] [Related]
43. BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. Shih HA; Couch FJ; Nathanson KL; Blackwood MA; Rebbeck TR; Armstrong KA; Calzone K; Stopfer J; Seal S; Stratton MR; Weber BL J Clin Oncol; 2002 Feb; 20(4):994-9. PubMed ID: 11844822 [TBL] [Abstract][Full Text] [Related]
44. The contribution of founder mutations in BRCA1 to breast cancer in Belarus. Uglanitsa N; Oszurek O; Uglanitsa K; Savonievich E; Lubiński J; Cybulski C; Debniak T; Narod SA; Gronwald J Clin Genet; 2010 Oct; 78(4):377-80. PubMed ID: 20507347 [TBL] [Abstract][Full Text] [Related]
45. Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. van Der Looij M; Wysocka B; Brozek I; Jassem J; Limon J; Olah E Hum Mutat; 2000 May; 15(5):480-1. PubMed ID: 10790213 [TBL] [Abstract][Full Text] [Related]
46. Usefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancers. Górski B; Debniak T; Jakubowska A; Cybulski C; Huzarski T; Byrski T; Złowocka E; Lubiński J J Appl Genet; 2003; 44(3):419-23. PubMed ID: 12923317 [TBL] [Abstract][Full Text] [Related]
47. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251 [TBL] [Abstract][Full Text] [Related]
48. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Pohlreich P; Zikan M; Stribrna J; Kleibl Z; Janatova M; Kotlas J; Zidovska J; Novotny J; Petruzelka L; Szabo C; Matous B Breast Cancer Res; 2005; 7(5):R728-36. PubMed ID: 16168118 [TBL] [Abstract][Full Text] [Related]
49. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Meindl A; Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209 [TBL] [Abstract][Full Text] [Related]
50. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149 [TBL] [Abstract][Full Text] [Related]
51. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. Ratajska M; Brozek I; Senkus-Konefka E; Jassem J; Stepnowska M; Palomba G; Pisano M; Casula M; Palmieri G; Borg A; Limon J Oncol Rep; 2008 Jan; 19(1):263-8. PubMed ID: 18097605 [TBL] [Abstract][Full Text] [Related]
52. [Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and primary multiple tumors involving the ovaries. Patients of Russian population using biochips]. Fedorova OE; Liubchenko LN; Paiadini IuG; Kazubskaia TP; Amosenko FA; Gar'kavtseva RF; Zasedatelev AS; Nasedkina TV Mol Biol (Mosk); 2007; 41(1):37-42. PubMed ID: 17380889 [TBL] [Abstract][Full Text] [Related]
53. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Verhoog LC; van den Ouweland AM; Berns E; van Veghel-Plandsoen MM; van Staveren IL; Wagner A; Bartels CC; Tilanus-Linthorst MM; Devilee P; Seynaeve C; Halley DJ; Niermeijer MF; Klijn JG; Meijers-Heijboer H Eur J Cancer; 2001 Nov; 37(16):2082-90. PubMed ID: 11597388 [TBL] [Abstract][Full Text] [Related]
54. Is there any relationship between BRCA1 gene mutation and pancreatic cancer development? Lawniczak M; Gawin A; Białek A; Lubiński J; Starzyńska T Pol Arch Med Wewn; 2008 Nov; 118(11):645-9. PubMed ID: 19140568 [TBL] [Abstract][Full Text] [Related]
55. The Potential Contribution of BRCA Mutations to Early Onset and Familial Breast Cancer in Uzbekistan. Abdikhakimov A; Tukhtaboeva M; Adilov B; Turdikulova S Cent Asian J Glob Health; 2016; 5(1):228. PubMed ID: 29138730 [TBL] [Abstract][Full Text] [Related]
56. Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania-Kujawy region of Poland. Janiszewska H; Haus O; Lauda-Swieciak A; Pasińska M; Laskowski R; Szymański W; Górski B; Lubiński J Clin Genet; 2003 Dec; 64(6):502-8. PubMed ID: 14986830 [TBL] [Abstract][Full Text] [Related]
57. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families. Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759 [TBL] [Abstract][Full Text] [Related]
58. [Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries]. Menkiszak J; Chudecka-Głaz A; Gronwald J; Bedner R; Cymbaluk-Płoska A; Wezowska M; Zielińska D; Rzepka-Górska I Ginekol Pol; 2013 Sep; 84(9):758-64. PubMed ID: 24191513 [TBL] [Abstract][Full Text] [Related]
59. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic]. Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209 [TBL] [Abstract][Full Text] [Related]
60. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]